IL-33 anticorps

N° du produit ABIN1169165

L’anticorps Lapin Polyclonal anti-IL-33 a été validé pour WB, ELISA et IHC. Il convient pour détecter IL-33 dans des échantillons de Humain. Il y a 1 publication disponible.

Aperçu rapide pour IL-33 anticorps (ABIN1169165)

Antigène: IL-33 (IL33) (Interleukin 33 (IL33))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IL-33 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Détail du produit anti-IL-33 anticorps

Specificité: Recognizes human IL-33. Detects a band of ~18 kDa by Western blot.

Réactivité croisée: Humain

Stérilité: 0.2 μm filtered

Immunogène: Recombinant human IL-33.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.

Agent conservateur: Without preservative

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C.

Date de péremption: 6 months

Références pour anticorps anti-IL-33 (ABIN1169165)

Carriere, Roussel, Ortega, Lacorre, Americh, Aguilar, Bouche, Girard: "IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 1, pp. 282-7, (2007) (PubMed).

Détails sur IL-33

Antigène: IL-33 (IL33) (Interleukin 33 (IL33))

Autre désignation: IL-33

Sujet: Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

UniProt: O95760

Pathways: Production of Molecular Mediator of Immune Response